← Eichor
Study identifier: NCT05592132 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Use of Virtual Reality in Pain Management in Pediatric Oncology

Condition: Pediatric Tumor  ·  Sponsor: Centre Hospitalier Universitaire de la Réunion

PhaseNA
Planned participants74
Who can joinAll sexes, 6 Years to 18 Years
Healthy volunteersNo

About this study

DOREVI is a monocentric randomized controlled study that will evaluate the efficacy of virtual reality helmets for pain prevention during invasive care on 78 oncologic pediatric patients. Two groups of children (between 6 and 11 and between 12 and 18 years old) will be randomized to use helmet plus standard care or standard care alone during invasive procedures (central venous catheter puncture, lumbar puncture, or bone marrow aspiration). The pain intensity will be evaluated using a visual analogic scale during three invasive procedures, and results will be compared between the patients with or without virtual reality.

This description comes directly from the study's public registry record.

Talk to the study team

Yves REGUERRE  ·  +262262905676  ·  yves.reguerre@chu-reunion.fr

Emilie TECHER  ·  +262262906289  ·  emilie.techer@chu-reunion.fr

Always discuss trial participation with your own doctor first.

Locations (1)

CHU de La RéunionSaint-Denis, ReunionRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05592132